Voltage-gated calcium channel antagonist and method
The present invention relates to a novel class of peptide compounds that specifically block class E voltage-gated calcium channels and to methods for blocking such channels. The invention also, relates to therapeutic treatments, such as treatment of convulsive disorders, using the compounds. A novel...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Newcomb, Robert Palma, Andrew L Szoke, Balazs G Tarczy-Hornoch, Katalin Hopkins, William F Cong, Ruth L Miljanich, George P Dean, Robin Nadasdi, Laszlo Urge, Laszlo Bowersox, Stephen Scott |
| description | The present invention relates to a novel class of peptide compounds that specifically block class E voltage-gated calcium channels and to methods for blocking such channels. The invention also, relates to therapeutic treatments, such as treatment of convulsive disorders, using the compounds.
A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_06653460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>06653460</sourcerecordid><originalsourceid>FETCH-uspatents_grants_066534603</originalsourceid><addsrcrecordid>eNrjZDAOy88pSUxP1U1PLElNUUhOzEnOLM1VSM5IzMtLzVFIzANK5udlFpcAmSkKuaklGfkpPAysaYk5xam8UJqbQcHNNcTZQ7e0uABoSl5JcXx6USKIMjAzMzU2MTMwJkIJAM37LUs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Voltage-gated calcium channel antagonist and method</title><source>USPTO Issued Patents</source><creator>Newcomb, Robert ; Palma, Andrew L ; Szoke, Balazs G ; Tarczy-Hornoch, Katalin ; Hopkins, William F ; Cong, Ruth L ; Miljanich, George P ; Dean, Robin ; Nadasdi, Laszlo ; Urge, Laszlo ; Bowersox, Stephen Scott</creator><creatorcontrib>Newcomb, Robert ; Palma, Andrew L ; Szoke, Balazs G ; Tarczy-Hornoch, Katalin ; Hopkins, William F ; Cong, Ruth L ; Miljanich, George P ; Dean, Robin ; Nadasdi, Laszlo ; Urge, Laszlo ; Bowersox, Stephen Scott ; Elan Pharmaceuticals, Inc</creatorcontrib><description>The present invention relates to a novel class of peptide compounds that specifically block class E voltage-gated calcium channels and to methods for blocking such channels. The invention also, relates to therapeutic treatments, such as treatment of convulsive disorders, using the compounds.
A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.</description><language>eng</language><creationdate>2003</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6653460$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6653460$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Newcomb, Robert</creatorcontrib><creatorcontrib>Palma, Andrew L</creatorcontrib><creatorcontrib>Szoke, Balazs G</creatorcontrib><creatorcontrib>Tarczy-Hornoch, Katalin</creatorcontrib><creatorcontrib>Hopkins, William F</creatorcontrib><creatorcontrib>Cong, Ruth L</creatorcontrib><creatorcontrib>Miljanich, George P</creatorcontrib><creatorcontrib>Dean, Robin</creatorcontrib><creatorcontrib>Nadasdi, Laszlo</creatorcontrib><creatorcontrib>Urge, Laszlo</creatorcontrib><creatorcontrib>Bowersox, Stephen Scott</creatorcontrib><creatorcontrib>Elan Pharmaceuticals, Inc</creatorcontrib><title>Voltage-gated calcium channel antagonist and method</title><description>The present invention relates to a novel class of peptide compounds that specifically block class E voltage-gated calcium channels and to methods for blocking such channels. The invention also, relates to therapeutic treatments, such as treatment of convulsive disorders, using the compounds.
A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2003</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZDAOy88pSUxP1U1PLElNUUhOzEnOLM1VSM5IzMtLzVFIzANK5udlFpcAmSkKuaklGfkpPAysaYk5xam8UJqbQcHNNcTZQ7e0uABoSl5JcXx6USKIMjAzMzU2MTMwJkIJAM37LUs</recordid><startdate>20031125</startdate><enddate>20031125</enddate><creator>Newcomb, Robert</creator><creator>Palma, Andrew L</creator><creator>Szoke, Balazs G</creator><creator>Tarczy-Hornoch, Katalin</creator><creator>Hopkins, William F</creator><creator>Cong, Ruth L</creator><creator>Miljanich, George P</creator><creator>Dean, Robin</creator><creator>Nadasdi, Laszlo</creator><creator>Urge, Laszlo</creator><creator>Bowersox, Stephen Scott</creator><scope>EFH</scope></search><sort><creationdate>20031125</creationdate><title>Voltage-gated calcium channel antagonist and method</title><author>Newcomb, Robert ; Palma, Andrew L ; Szoke, Balazs G ; Tarczy-Hornoch, Katalin ; Hopkins, William F ; Cong, Ruth L ; Miljanich, George P ; Dean, Robin ; Nadasdi, Laszlo ; Urge, Laszlo ; Bowersox, Stephen Scott</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_066534603</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2003</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Newcomb, Robert</creatorcontrib><creatorcontrib>Palma, Andrew L</creatorcontrib><creatorcontrib>Szoke, Balazs G</creatorcontrib><creatorcontrib>Tarczy-Hornoch, Katalin</creatorcontrib><creatorcontrib>Hopkins, William F</creatorcontrib><creatorcontrib>Cong, Ruth L</creatorcontrib><creatorcontrib>Miljanich, George P</creatorcontrib><creatorcontrib>Dean, Robin</creatorcontrib><creatorcontrib>Nadasdi, Laszlo</creatorcontrib><creatorcontrib>Urge, Laszlo</creatorcontrib><creatorcontrib>Bowersox, Stephen Scott</creatorcontrib><creatorcontrib>Elan Pharmaceuticals, Inc</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Newcomb, Robert</au><au>Palma, Andrew L</au><au>Szoke, Balazs G</au><au>Tarczy-Hornoch, Katalin</au><au>Hopkins, William F</au><au>Cong, Ruth L</au><au>Miljanich, George P</au><au>Dean, Robin</au><au>Nadasdi, Laszlo</au><au>Urge, Laszlo</au><au>Bowersox, Stephen Scott</au><aucorp>Elan Pharmaceuticals, Inc</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Voltage-gated calcium channel antagonist and method</title><date>2003-11-25</date><risdate>2003</risdate><abstract>The present invention relates to a novel class of peptide compounds that specifically block class E voltage-gated calcium channels and to methods for blocking such channels. The invention also, relates to therapeutic treatments, such as treatment of convulsive disorders, using the compounds.
A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_06653460 |
| source | USPTO Issued Patents |
| title | Voltage-gated calcium channel antagonist and method |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A31%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Newcomb,%20Robert&rft.aucorp=Elan%20Pharmaceuticals,%20Inc&rft.date=2003-11-25&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E06653460%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |